Author:
Mershon J. Patrick,Rodriguez Brianna,McIntosh Stephanie,Crescenze Iryna
Publisher
Springer Science and Business Media LLC
Reference89 articles.
1. Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol. 2012;188(6):2455–63.
2. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37–49.
3. Krhut J, Skugarevská B, Míka D, Lund L, Zvara P. Clinical utility of β(3)-adrenoreceptor agonists for the treatment of overactive bladder: a review of the evidence and current recommendations. Res Rep Urol. 2022;14:167–75.
4. ∙Fontaine C, Papworth E, Pascoe J, Hashim H. Update on the management of overactive bladder. Ther Adv Urol. 2021;13:17562872211039034. An excellent comprehensive review of management options
5. McFerren SC, Gomelsky A. Treatment of overactive bladder in the elderly female: the case for trospium, oxybutynin. Fesoterodine Darifenacin Drugs Aging. 2015;32(10):809–19.